"GlaxoSmithLine (GSK) the manufacturer of Cervarix has recently conducted a trial of its two valent HPV vaccine on healthy 4-6 year old female children in Latin America."
"The study involving girls from Colombia, Panama and Mexico was published in the current edition of the Pediatric Infectious Disease Journal. "
"Here is the stated rationale for injecting such young children with HPV vaccines:"
"The burden of human papillomavirus (HPV) diseases is high in Latin America. HPV vaccines licensed from 2006 onwards offer protection against most HPV-related cancers, especially when introduced into national immunization programs."
"Barriers to optimal vaccine uptake are, however, lowering the impact of adolescent HPV vaccination programs. Immunization of children might overcome these barriers and be a strategy of choice for some countries."